1 EXHIBIT 10.57 CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.800(b)(4), 200.83 and 240.24b-2 [GENE LOGIC LETTERHEAD] September 28, 1999 Mr. K. Kiyose Japan Tobacco Inc. Pharmaceutical Division JT Building 2-1, Toranomon 2-chome...Drug Target and Drug Lead Discovery Collaboration Agreement • November 15th, 1999 • Gene Logic Inc • Services-commercial physical & biological research
Contract Type FiledNovember 15th, 1999 Company Industry
TEXT OMITTED AND FILED SEPARATELY CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 240.24b-2 [GENE LOGIC LETTERHEAD] December 28, 1998 Mr. K. Kiyose Japan Tobacco Inc. Pharmaceutical Division JT Building 2-1,...Drug Target and Drug Lead Discovery Collaboration Agreement • March 31st, 1999 • Gene Logic Inc • Services-commercial physical & biological research
Contract Type FiledMarch 31st, 1999 Company Industry